You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

463 Results
Document
Dec 1969
Document
Dec 1969
In October 2024, the Ontario Breast Screening Program lowered the starting age for screening from age 50 to age 40.This page provides breast cancer...
Imprimer Ces renseignements doivent aider les fournisseurs de soins de santé à se préparer à mener des conversations avec leurs patientes et...
Document
Oct 2024
Document
Oct 2024
Document
Nov 2024
Document
Nov 2024
Guidelines and Advice
Status: Current
ID: GL END 7-24
Nov 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    abiraterone
Exceptional Access Program
    olaparib - In combination with abiraterone, and prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC), based on criteria
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
abiraterone,
olaparib,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Guidelines and Advice
Status: Current
ID: Guideline Endorsement C50-CIDAP-2
Nov 2024
Document
Jan 2025

Pages